Glaxo Sells Rights to Auto-Immune Drug to Novartis

LONDON (MarketWatch) – GlaxoSmithKline PLC is selling its remaining rights to a drug for use in treating autoimmune diseases, including multiple sclerosis, to Novartis AG for up to $1 billion, plus royalties. Glaxo said on Friday that Novartis will own rights to ofatumumab, as the Read More